Significant unmet treatment need exists for a range of serious autoantibody mediated autoimmune diseases, including certain neurologic and neuromuscular disorders. Johnson & Johnson is committed to deepening our research in neurologic and neuromuscular conditions to help address the significant unmet need for therapies and treatments for patients with a pathway-based approach.
